Jutta Deckert
Vice President, R&D Iksuda Therapeutics
Seminars
Thursday 6th November 2025
Workshop highlights include:
- Accurately characterizing antibody, linker, payload, and overall conjugate contributions to ADC clinical performance
- Contrasting different clinical profiles of ADCs differing in only one design componentÂ
- Optimizing ADC design to pair the right payload with the right targetÂ
Wednesday 5th November 2025
Exploring Preclinical Characterization of IKS04 in GI Cancer & Assessing Impact of Unconjugated Antibody Co-Dosing on Tumor Penetration
2:00 pm
- Introducing IKS04 ultra-low DAR approach with a highly potent payload targeting CA242 in GI cancer
- Explaining rationale and preclinical data for co-dosing with antibodies to improve tumor uptake of potent payload ADCs
- Reviewing the preclinical profile of IKS04 and highlighting future plans for clinical investigation
Tuesday 4th November 2025
Chair:
Download the Full Event Guide for full details
